Sundar, S., & Dickinson, P. D. (2012). Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate. BMJ Publishing Group.
Chicago Stili AlıntıSundar, Santhanam, ve Peter D. Dickinson. Spironolactone, a Possible Selective Androgen Receptor Modulator, Should Be Used With Caution in Patients With Metastatic Carcinoma of the Prostate. BMJ Publishing Group, 2012.
MLA AlıntıSundar, Santhanam, ve Peter D. Dickinson. Spironolactone, a Possible Selective Androgen Receptor Modulator, Should Be Used With Caution in Patients With Metastatic Carcinoma of the Prostate. BMJ Publishing Group, 2012.
Uyarı: Bu alıntı herzaman %100 doğru olmayabilir..